cGxP.wire https://validator.w3.org/feed/docs/rss2.html Celldex Reports Phase 2 Barzolvolimab Results in Prurigo Nodularis Nurix and Roche Complete Strategic Oncology Collaboration Rein Therapeutics Expands Phase 2 RENEW Trial Across Five Countries Telix Publishes ProstACT SELECT Study on TLX591-Tx Plus Therapeutics Secures Medical Mutual Coverage Agreement Akari and Whitehawk Launch ADC Research Partnership Enterome Reports Positive Phase 2 EO2463 Results Kyowa Kirin Wins EC Approval for Crysvita in Infants Haier Biomedical Unveils Digital Blood Management Platform Tempus to Acquire Personalis in $1.5B Precision Oncology Deal Bluejay Completes Patient Enrollment in SYMON-II Trial AdaptHealth Signs Definitive Sale Agreement with Cardinal Health Acadia Secures FDA Fast Track for Alzheimer’s Psychosis Drug Aptar Beauty Expands Packaging Innovation with NeoDropper Stereotaxis Launches Hungary’s First Robotic Cardiology Program Innate Pharma Reaches Phase 1 Enrollment Milestone for IPH4502 Fuse Oncology Unveils FuseRx to Transform Radiation Care Alliance for Building Better Medicine Secures $15.97M EDA Grant OMEICOS Advances OMT-28 to Phase 3 After FDA Meeting King Faisal Performs First Single-Incision Robotic Liver Transplant BIOTRONIK Neuro Launches AI-Powered Embrace One Platform Spectrum Dynamics Launches VERITON-CT 400 Enhancement AbelZeta Earns EMA PRIME for C-CAR168 Lupus Therapy Argo Biopharma Doses First Patient in BW-41012 Trial Valion Bio, Sheba Advance Entolimod Cancer Trial Lupin Spins Out Oncology Pipeline to Kaveri Therapeutics Organon, Samsung Bioepis Strengthen Australia Biosimilar Portfolio ARUP Launches First Clinical Spectral Flow MRD Assay Akeso Starts Phase II Trial of AK146D1 for Advanced NSCLC Oncolytics Biotech Wins FDA Fast Track for Pelareorep Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx Kinaset Doses First Patient in Phase 2b Frevecitinib Trial Belite Bio Reports Positive Phase 3 Tinlarebant Data at ASRS 2026 Adaptix Partners with Spartan Medical for U.S. Expansion VERAXA Achieves Key Regulatory Milestone for BiTAC-TCE Dyne Therapeutics Advances DMD Program with FDA Acceptance Immunome Doses First Patient in Phase 1 IM-3050 Radioligand Therapy Trial Marengo Reports Phase II Breast Cancer Trial Success Lundbeck Completes Enrollment in Phase III DEEp OCEAN Trial Bristol Myers Squibb Expands AI Collaboration with NVIDIA Samsung Biologics to Acquire PolyPeptide for CHF 1.46B Can-Fite Phase 2a Namodenoson Pancreatic Cancer Data Accepted at ESMO 2026 SystImmune Advances Oncology Portfolio with Iza-bren Approval Harrow Highlights New IHEEZO and BYOOVIZ Clinical Evidence at ASRS 2026 REGENXBIO Reports Positive Long-Term Gene Therapy Results GSK Seeks EMA Approval for Bexsero Booster Vaccine Update OKYO Pharma Boosts Cash to Advance Phase 3 Urcosimod Trial BioLineRx to Present GLIX1 Ovarian Cancer Data at ESMO 2026 INmune Bio Reaches Commercial CORDStrom Manufacturing Milestone Armata Advances AP-SA02 Toward Phase III Bacteremia Trial